423 related articles for article (PubMed ID: 24378070)
1. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
2. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma.
Chae AW; Martinez SR
Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
4. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
5. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
Podnos YD; Smith DD; Wagman LD; Ellenhorn JD
J Surg Oncol; 2007 Jul; 96(1):3-7. PubMed ID: 17567872
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
7. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
8. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer.
Ruel E; Thomas S; Perkins JM; Roman SA; Sosa JA
Ann Surg Oncol; 2017 Jul; 24(7):1935-1942. PubMed ID: 28127652
[TBL] [Abstract][Full Text] [Related]
10. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer.
Sawka AM; Straus S; Rotstein L; Brierley JD; Tsang RW; Asa S; Segal P; Kelly C; Zahedi A; Freeman J; Solomon P; Anderson J; Thorpe KE; Gafni A; Rodin G; Goldstein DP
J Clin Oncol; 2012 Aug; 30(23):2906-11. PubMed ID: 22753906
[TBL] [Abstract][Full Text] [Related]
12. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
13. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
[TBL] [Abstract][Full Text] [Related]
14. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
15. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
Grigsby PW; Reddy RM; Moley JF; Hall BL
Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Fatani H; AlHadab A
J Otolaryngol Head Neck Surg; 2015 Dec; 44():51. PubMed ID: 26621255
[TBL] [Abstract][Full Text] [Related]
17. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
20. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]